Session » Abstracts: Reproductive Issues in Rheumatic Disorders

Date: Monday, November 13, 2023

Time: 4:00PM-5:30PM

Meeting: ACR Convergence 2023

Abstract Number: 1681

Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers

Abstract Number: 1682

Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block

Abstract Number: 1683

Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO

Abstract Number: 1684

The Impact of Pregnancy Timing on Outcomes in SLE

Abstract Number: 1685

SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients

Abstract Number: 1686

Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.